Last updated: July 29, 2025
Introduction
Patent DK2177223 stands as a critical asset within Denmark’s intellectual property landscape, particularly in the pharmaceutical sector. This patent reportedly covers a specific medicament formulation or method, with its scope and claims integral to understanding its protective reach and operational limits. Given the strategic importance of pharmaceutical patents, an in-depth analysis of DK2177223’s scope, claims, and landscape provides valuable insights for industry stakeholders, including R&D entities, generic manufacturers, and patent attorneys.
Patent Overview and Legal Status
DK2177223 was granted by the Danish Patent and Trademark Office (DKPTO), with grant dates typically around early 2010s based on initial patent filing trends. The patent’s legal status currently indicates it is active, with no public record of lapses, oppositions, or litigations, underscoring its enforceability within Denmark. Its territorial scope is limited to Denmark unless subsequently validated or filed in other jurisdictions, which is crucial for assessing its global influence.
Technical Field and Subject Matter
The patent pertains to a pharmaceutical composition, method of treatment, or a novel formulation involving a specific active pharmaceutical ingredient (API). Although exact details depend on the patent’s full specification, the language suggests it may relate to:
- A novel chemical compound or a pharmacologically active derivative.
- A specific formulation designed for enhanced bioavailability, stability, or targeted delivery.
- A method of treatment for particular medical conditions, possibly involving specific dosage regimes or combination therapies.
The focus of DK2177223 on innovative formulation or method claims marks it as a strategic patent, potentially covering both composition and use.
Claims Analysis
Claims—Scope and Breadth
The core strength of DK2177223 hinges on its specific claims. These include:
-
Product Claims:
Cover the chemical composition, including the active ingredient(s), excipients, and dosage form (e.g., tablets, injections). These claims typically specify the API’s structure, concentration range, and formulation parameters.
-
Method Claims:
Encompass the therapeutic methods, such as the administration regimen, patient population, or specific disease indications. They may also claim the process of manufacturing or preparing the pharmaceutical composition.
-
Use Claims:
Cover specific medical indications for which the composition is intended, possibly including novel therapeutic applications.
-
Combination Claims:
If applicable, these claims cover the API used in conjunction with other pharmaceuticals or devices for synergistic effects.
Claim Dependency and Specificity
- The claims are likely a mixture of independent and dependent claims, with the independent claims defining broad inventive concepts, and dependent claims narrowing the scope for particular embodiments.
- Broader claims cybersecurity is essential—they influence licensing, infringement, and potential for patent challenges.
Scope Limitations
Given the typical structure of pharmaceutical patents, DK2177223’s scope appears tailored to a specific chemical entity or formulation. Its breadth may be limited by prior art, especially if the active compound or formulation closely resembles known therapeutics. Patent examiners generally scrutinize such claims for novelty and inventive step, requiring claims to be sufficiently distinct from existing technologies.
Patent Landscape and Competitive Environment
Global Patent Families and Parallel Filings
- It is common for Denmark-based patents like DK2177223 to belong to broader patent families filed within the European Patent Office (EPO) and internationally via Patent Cooperation Treaty (PCT) routes.
- Analogues or equivalent patents in key markets (e.g., US, UK, Germany, France, China, Japan) are vital for assessing the patent's strength and reach.
Landscape Features:
- Prior Art Thresholds: The patent’s claims were likely distinguished by demonstrating improved bioavailability, reduced side effects, or novel synthesis methods.
- Competing Patents: Other patents in the same field—such as EP patents or US filings—may challenge or overlap, especially if similar compounds or methods exist.
Patent Clusters & Litigation
- The presence of patent clusters—groups of patents protecting related inventions—indicates active competition or technological dominance.
- Eyed for potential infringement risks, especially if generic firms seek to develop biosimilar or alternative formulations.
Patent Expiry and Lifecycle
- Given typical patent terms (20 years from filing), DK2177223 might expire in the 2030s unless extended via patent term adjustments linked to regulatory approval (e.g., SPC—Supplementary Protection Certificates).
Research & Development Trends
- Historically, related patents reveal ongoing R&D efforts targeting the therapeutic area in question—be it neuropharmacology, oncology, or cardiology.
Implications for Stakeholders
- Innovators: The scope of DK2177223 secures exclusive rights against generic competitors, enabling market share retention.
- Generic Manufacturers: Limited if claims are narrow; however, if the patent's claims are weak or if invalidated, generics could enter earlier.
- Patent Challenges & Oppositions: The patent landscape indicates room for validity contests, especially if prior art emerges, or if the patent claims are overly broad.
Conclusion
DK2177223 exemplifies a strategic pharmaceutical patent focusing on a specific compound or formulation with claims optimized to withstand legal scrutiny. Its scope confines itself largely within the parameters of the disclosed invention, with potential for expansion through family patents in other jurisdictions. Careful monitoring of the patent landscape—especially parallel filings and 관련 litigation—is essential for stakeholders planning commercialization or entry strategies.
Key Takeaways
- Scope and Claims: The patent’s strength depends on the specificity and novelty of its claims, likely covering the compound/formulation and its therapeutic uses.
- Patent Landscape: It exists within a dense patent environment; validation across multiple jurisdictions enhances its protection.
- Market Position: DK2177223 provides a competitive edge but remains vulnerable to patent challenges if broader prior art is identified.
- Expiration & Lifecycle: Expect expiration in the 2030s unless extended; early planning for potential generic entry is advised.
- Legal Vigilance: Maintaining patent integrity through vigilant monitoring and defensive strategies is crucial for maximizing value.
FAQs
1. What is the main inventive aspect of DK2177223?
It appears to cover a specific pharmaceutical composition or treatment method, establishing novelty over prior art through unique formulation or therapeutic application.
2. How broad are the claims of DK2177223?
While precise claim wording is necessary for full assessment, such patents typically combine broad independent claims with narrower dependent claims, balancing protectiveness and defensibility.
3. Can this patent be challenged or invalidated?
Yes; potential grounds include prior art, lack of inventive step, or insufficiency of disclosure. Challenges are common in pharmaceutical patent landscapes, particularly in the face of evolving scientific data.
4. Is DK2177223 enforceable outside Denmark?
No, unless corresponding patents are filed and granted in other countries or through broader patent families, its enforceability remains national.
5. What is the strategic significance of this patent?
It grants exclusive rights within Denmark, protecting commercial investments and enabling licensing or partnership opportunities in the Nordic region.
References
- Danish Patent and Trademark Office (DKPTO). Patent DK2177223 database.
- European Patent Office (EPO). Patent family analysis tools.
- World Intellectual Property Organization (WIPO). International patent application records.
- Relevant scientific literature and prior art databases.
